{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-04-15",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 1
    }
  },
  "results": [
    {
      "status": "Terminated",
      "city": "Frederick",
      "state": "MD",
      "country": "United States",
      "classification": "Class II",
      "openfda": {},
      "product_type": "Devices",
      "event_id": "79649",
      "recalling_firm": "Life Technologies Corporation",
      "address_1": "7335 Executive Way",
      "address_2": "N/A",
      "postal_code": "21704-8354",
      "voluntary_mandated": "Voluntary: Firm initiated",
      "initial_firm_notification": "Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit",
      "distribution_pattern": "Distributed to states: AZ, CA, NC, TX, and VA.",
      "recall_number": "Z-1480-2018",
      "product_description": "Oncomine Dx Target Test, (Model No. A32451), Oncomine Dx Target RNA/DNA Panel (Model No. A32441).    A qualitative In Vitro Diagnostic test.",
      "product_quantity": "30",
      "reason_for_recall": "The lower concentration of the RNA panel could cause a NO CALL or FALSE NEGATIVE for the reporting of ROS1 fusion.  If a physician relies on a false negative result, crizotinib could be improperly excluded from the patient's treatment regimen.",
      "recall_initiation_date": "20180208",
      "center_classification_date": "20180420",
      "termination_date": "20200512",
      "report_date": "20180502",
      "code_info": "Lot 1705001  UDI: (01)10190302006385(17)180220(10)1705001(240)A32441"
    }
  ]
}